Theranos withdraws new Zika test after FDA inspection: WSJ

(Reuters) - Blood-testing firm Theranos Inc withdrew its request for emergency clearance of a Zika-virus blood test after U.S. regulators found the company did not include proper patient safeguards in a study on the test, The Wall Street Journal reported, citing people familiar with the matter. Theranos was not immediately available for comment. The diagnostic test for Zika can detect additional strains of the mosquito-borne virus from blood drops finger-pricked from patients, Theranos CEO Eliza